fda status bpc-157 tb-500 2025 or 2026 Peptide Sciences Shuts Down: What Happened (March 2026) FDA Staff: No Compounding for
Description
In the STEP 8 phase III trial for semaglutide 2.4 mg, participants self-injected 3,864 times with only 22 reported errors, most of which were minor observations of liquid on the skin
The critical factor for choosing a vendor remains verifiable, up-to-date Certificates of Analysis (COA) confirming 99% purity, competitive pricing, and fast domestic shipping
Physical symptoms often include weakness, pale or jaundiced skin, and a smooth, red tongue that might feel sore
No changes in cancer markers, hormones, liver, or kidney function reported (only monitored in the short term days)
